By: ABRS- Academic Team
Introduction
Outsourcing has become an integral part of modern clinical development. Sponsors routinely rely on contract research organizations, Functional Service Providers, technology vendors, central laboratories, safety providers, and regional specialists to access capabilities that may not be available internally. This allows organizations to expand into new countries, respond to changing study demands, and obtain specialized expertise without having to build every function in-house.
However, transferring clinical trial activities does not transfer the sponsor’s ultimate accountability for how those activities are performed. The sponsor must still understand whether critical processes are functioning as intended, whether risks are being identified and escalated, and whether participants and trial data are being adequately protected.
ICH E6(R3) makes this distinction increasingly important. The guideline gives sponsors flexibility to design oversight and quality-management approaches suited to the characteristics of each trial, but that flexibility is accompanied by a clear expectation: sponsors must remain informed, retain access to relevant information, and exercise oversight proportionate to the importance and risk of the outsourced activities.
This does not mean that sponsors must recreate the work assigned to their partners or become involved in every operational decision. Effective oversight is not duplication. It is the ability to establish expectations, evaluate performance, identify meaningful risks, and intervene when the trial requires sponsor-level action.
A properly designed FSP partnership can support this responsibility by giving sponsors direct access to experienced professionals who work within their governance structure. When roles, information flows, escalation pathways, and performance expectations are clearly established, outsourcing can strengthen sponsor control rather than weaken it.
Delegation Changes Who Performs the Work—Not Who Owns the Outcome
One of the most important clarifications in ICH E6(R3) concerns the relationship between sponsors and service providers. Sponsors may transfer trial-related activities, but the agreements must identify what has been transferred and what remains under the sponsor’s direct responsibility. The guideline also establishes that ultimate responsibility for participant protection and the reliability of trial data continues to reside with the sponsor, including when activities are further subcontracted by a service provider (International Council for Harmonisation, 2025).
This distinction has significant practical implications. Signing a contract and assigning responsibilities are only the beginning of an outsourcing relationship. Sponsors must also determine whether the selected provider is suitable for the work, whether the provider’s quality-management processes are appropriate, and whether the sponsor will have access to the information needed to evaluate performance.
Contracts should therefore describe more than deliverables and timelines. They should establish ownership of decisions, reporting expectations, escalation requirements, access to systems and records, management of subcontractors, and the evidence that will demonstrate ongoing oversight. When these elements remain unclear, gaps can emerge between what the sponsor assumes is being controlled and what the provider is actually managing.
Inspection experience illustrates the consequences of those gaps. MHRA case studies have documented critical and major findings where sponsors lacked visibility into delegated pharmacovigilance activities, protocol deviations, monitoring reports, essential documents, and vendor-held Trial Master Files. In some cases, sponsors had contractual arrangements but could not reconstruct how they had supervised the outsourced activities while the trial was underway (Medicines and Healthcare products Regulatory Agency, 2018).
The lesson is not that outsourcing itself creates noncompliance. The underlying risk arises when operational delegation is not supported by a functioning oversight mechanism. A provider may complete assigned tasks, but the sponsor must still receive enough information to determine whether those tasks are protecting participants, supporting reliable results, and complying with the protocol and applicable requirements.
This is particularly relevant in FSP arrangements because functional professionals often work closely with sponsor teams, systems, and procedures. That proximity can provide greater transparency than a fully outsourced model, but only when responsibilities are deliberately designed. Reporting lines, decision rights, issue ownership, and communication expectations should be established before activities begin and reviewed as the study evolves.
Within the ABRS Global FSP model, functional delegation is supported by clearly defined responsibilities and direct collaboration with sponsor teams. Regional professionals can execute assigned activities while remaining connected to the sponsor’s governance, quality expectations, and escalation structure. This helps preserve the sponsor’s visibility without creating unnecessary duplication of operational work.
Oversight Works Best When It Follows the Risk
Sponsor oversight should not become an administrative exercise in which every activity receives the same level of review. Trials differ in design, therapeutic area, participant population, geographic reach, technology, endpoints, and operational complexity. The oversight model should reflect those differences.
The FDA’s guidance on risk-based monitoring explains that monitoring strategies should be planned around the risks that matter most to trial conduct. Monitoring is intended to determine whether activities are being performed as expected, but the approach should prioritize participant protection, data reliability, protocol compliance, and the communication of significant findings rather than relying automatically on uniform review practices (U.S. Food and Drug Administration, 2023).
Applying this principle to an outsourced operating model means that oversight should concentrate on critical processes and decisions. For example, safety reporting, informed consent, eligibility, primary endpoint data, investigational product management, important protocol deviations, and the timely escalation of systemic site issues may require closer attention than routine administrative activities.
The intensity of oversight should also consider the experience of the provider, the maturity of its quality systems, the complexity of the transferred function, historical performance, and the potential impact of failure. A sponsor working with an established provider in a familiar therapeutic area may use a different oversight approach than one entering a new region or relying on a provider for a highly specialized function.
MHRA guidance similarly recommends that sponsors begin with a structured assessment of trial risks and document how oversight and monitoring activities will mitigate them. It identifies tools such as monitoring plans, committee charters, data-management plans, pharmacovigilance plans, vendor meetings, central reviews, audits, and escalation procedures. The guidance also emphasizes linking these documents so that they operate as a coherent strategy, especially when responsibilities are distributed among CROs or providers in different countries (Medicines and Healthcare products Regulatory Agency, 2022).
This approach allows sponsors to avoid two common extremes. The first is insufficient oversight, where the sponsor receives information only after a major issue has developed. The second is excessive oversight, where teams spend substantial time reviewing low-value details without improving participant protection or data quality.
A more effective model uses predefined indicators and escalation triggers. These may include recurring important protocol deviations, delayed safety reporting, unresolved monitoring findings, repeated data-quality issues, site-capacity concerns, missed milestones, inadequate documentation, staff turnover, or inconsistent application of sponsor procedures.
For ABRS, risk-based oversight requires more than providing experienced professionals. It also means ensuring that functional teams understand which issues are critical, how they must be communicated, and when sponsor involvement is necessary. This enables regional professionals to respond to local operational realities while remaining aligned with the sponsor’s broader risk and quality framework.
A Strong FSP Partnership Should Increase Sponsor Visibility
Outsourcing can expand clinical development capacity, accelerate access to specialized expertise, and help sponsors operate across multiple countries. Yet those advantages depend on a clear understanding of what can—and cannot—be transferred.
Clinical trial activities may be assigned to service providers, but the sponsor continues to own the ultimate responsibility for participant protection, data reliability, and the quality of trial conduct. ICH E6(R3) reinforces that accountability while giving sponsors the flexibility to build oversight approaches proportionate to each trial’s risks and complexity.
Effective oversight is not achieved through additional meetings, larger reports, or the duplication of every outsourced task. It depends on clear responsibilities, qualified providers, access to relevant information, meaningful performance measures, documented decisions, and escalation processes that function when the trial needs them.
A well-integrated FSP model can help sponsors meet these expectations. By placing experienced professionals within the sponsor’s operating framework, the model can combine flexible functional capacity with direct communication, regional expertise, and transparent performance oversight.
At ABRS, our Global FSP approach is built to support sponsor control rather than replace it. We connect qualified clinical research professionals with sponsor governance, quality systems, and study-specific priorities so that operational responsibilities can be delegated without losing visibility or accountability.
As clinical trials become more complex and increasingly dependent on external expertise, the strongest outsourcing partnerships will be those that make sponsor oversight easier to exercise and easier to demonstrate. The real value of an FSP relationship is therefore not measured only by the resources it provides, but by its ability to help the sponsor remain informed, responsive, and confidently in control.
Conclusion:
Scaling global clinical operations successfully requires more than expanding into new markets or increasing operational capacity. It requires a balanced approach that combines standardized governance, consistent quality, and the flexibility to respond to the unique characteristics of every region where a study is conducted.
Organizations that integrate global oversight with local expertise are better equipped to strengthen collaboration, improve site relationships, support regulatory compliance, and maintain operational consistency across increasingly complex clinical programs. This combination enables sponsors to make informed decisions while adapting efficiently to regional challenges without compromising quality or performance.
At ABRS, we believe that global success is achieved through meaningful local partnerships supported by a unified operational framework. Our Global FSP model combines experienced regional professionals, structured governance, and a commitment to operational excellence, allowing sponsors to execute clinical trials with confidence across diverse healthcare environments.
As the future of clinical research continues to evolve, the ability to connect global strategy with local execution will remain one of the defining characteristics of successful clinical development. Sponsors who invest in collaborative partnerships built on expertise, governance, and regional knowledge will be better positioned to accelerate innovation and deliver meaningful outcomes for patients around the world.
